Leveraging Predictive Analytics for Pharmaceutical Innovation

March 20, 2019

Pharmaceutical companies aiming to develop innovative new therapies and treatments face many challenges. Without proper processes and systems in place, it is very difficult to replicate successful results, mitigate failures, reduce product variability and ultimately deliver a new therapy to market. Having competent control and visibility over each step of the development process, from early stage ideation through scale up and production, is becoming increasingly important in modern laboratory facilities. This includes not only having total control over laboratory operations but also the proper documentation to prove process control for quality and regulatory compliance. A critical factor in optimizing efficiencies and control is to ensure that a life science laboratory is both safe and predictable. Safeguarding a state-of-the-art, innovation-based laboratory is no easy task and requires foresight, experience, and attention to detail. With this in mind, many pharmaceutical companies opt for a proactive, rather than reactive, approach to monitoring and protecting valuable life science facilities, assets and equipment. 

Spotlight

Fera Pharmaceuticals

Fera is a specialty pharmaceutical company interested in acquiring and licensing ANDAs and NDAs, pursuing its own product development and partnering with companies in need of commercialization and marketing support.

OTHER WHITEPAPERS
news image

A Vision for the Global Generic and Biosimilar Medicines Industry

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

THE PHARMACEUTICAL INDUSTRY AND GLOBAL HEALTH

whitePaper | January 31, 2022

COVID-19 is an infectious disease caused by a newly discovered coronavirus, which was first identified in December 2019.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More

Spotlight

Fera Pharmaceuticals

Fera is a specialty pharmaceutical company interested in acquiring and licensing ANDAs and NDAs, pursuing its own product development and partnering with companies in need of commercialization and marketing support.

Events